Skip to Content
Merck
  • Synthesis and structure-activity relationship of 6-arylureido-3-pyrrol-2-ylmethylideneindolin-2-one derivatives as potent receptor tyrosine kinase inhibitors.

Synthesis and structure-activity relationship of 6-arylureido-3-pyrrol-2-ylmethylideneindolin-2-one derivatives as potent receptor tyrosine kinase inhibitors.

Bioorganic & medicinal chemistry (2010-06-24)
Rahul R Khanwelkar, Grace Shiahuy Chen, Hsiao-Chun Wang, Chao-Wu Yu, Chiung-Hua Huang, On Lee, Chih-Hung Chen, Chrong-Shiong Hwang, Ching-Huai Ko, Nien-Tzu Chou, Mai-Wei Lin, Ling-Mei Wang, Yen-Chun Chen, Tzong-Hsiung Hseu, Chia-Ni Chang, Hui-Chun Hsu, Hui-Chi Lin, Ying-Chu Shih, Shuen-Hsiang Chou, Hsiang-Wen Tseng, Chih-Peng Liu, Chia-Mu Tu, Tsan-Lin Hu, Yuan-Jang Tsai, Ji-Wang Chern
ABSTRACT

A series of new ureidoindolin-2-one derivatives were synthesized and evaluated as inhibitors of receptor tyrosine kinases. Investigation of structure-activity relationships at positions 5, 6, and 7 of the oxindole skeleton led to the identification of 6-ureido-substituted 3-pyrrolemethylidene-2-oxindole derivatives that potently inhibited both the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) families of receptor tyrosine kinases. Several derivatives showed potency against the PDGFR inhibiting both its enzymatic and cellular functions in the single-digit nanomolar range. Among them, compound 35 was a potent inhibitor against tyrosine kinases, including VEGFR and PDGFR families, as well as Aurora kinases. Inhibitor 36 (non-substituted on the pyrrole or phenyl ring) had a moderate pharmacokinetic profile and completely inhibited tumor growth initiated with the myeloid leukemia cell line, MV4-11, in a subcutaneous xenograft model in BALB/c nude mice.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
2-Oxindole, 97%